Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8193641 | 0.86 | HDAC6 (0.48) | RXFP1KMT2AMEN1HDAC6MAPT | |
| SCHEMBL3203228 | 0.85 | CYP4F2 (0.47) | RXFP1KMT2AMEN1HDAC6MAPT | |
| SCHEMBL20302731 | 0.78 | MAPT (0.47) | RXFP1KMT2AMEN1MAPTBACE1 | |
| SCHEMBL20303195 | 0.78 | MAPT (0.47) | RXFP1KMT2AMEN1MAPTBACE1 | |
| SCHEMBL7563909 | 0.76 | RXFP1 (0.45) | RXFP1KMT2AMEN1HDAC6BACE1 | |
| SCHEMBL2970444 | 0.75 | RXFP1 (0.43) | RXFP1KMT2AMEN1HDAC6MAPT | |
| SCHEMBL20302834 | 0.75 | MAPT (0.54) | KMT2AMEN1MAPTL3MBTL1ABHD6 | |
| SCHEMBL12410375 | 0.73 | RXFP1 (0.41) | RXFP1KMT2AMEN1HDAC6MAPT | |
| SCHEMBL7539492 | 0.73 | RXFP1 (0.41) | RXFP1KMT2AMEN1BACE1NPC1 | |
| SCHEMBL7511170 | 0.71 | MAPT (0.48) | MAPTHTTL3MBTL1ABHD6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1902057-B1 | MACROCYCLIC HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-1902057-B1 | MACROCYCLIC HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-10-23 | — | — | EP | disclosed |
| US-8557798-B2 | Macrocyclic heterocyclic aspartyl protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557798-B2 | Macrocyclic heterocyclic aspartyl protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557798-B2 | Macrocyclic heterocyclic aspartyl protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| US-7812013-B2 | Macrocyclic heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812013-B2 | Macrocyclic heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812013-B2 | Macrocyclic heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2010-10-12 | — | — | US | disclosed |
| US-20100063121-A1 | Macrocyclic Heterocyclic Aspartyl Protease Inhibitors | SCHERING CORPORATION | 2010-03-11 | — | — | US | disclosed |
| US-20100063121-A1 | Macrocyclic Heterocyclic Aspartyl Protease Inhibitors | SCHERING CORPORATION | 2010-03-11 | — | — | US | disclosed |
| US-20100063121-A1 | Macrocyclic Heterocyclic Aspartyl Protease Inhibitors | SCHERING CORPORATION | 2010-03-11 | — | — | US | disclosed |
| US-20060281729-A1 | Macrocyclic heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION | 2006-12-14 | — | — | US | disclosed |
| US-20060281729-A1 | Macrocyclic heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION | 2006-12-14 | — | — | US | disclosed |
| US-20060281729-A1 | Macrocyclic heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063121-A1 | Macrocyclic Heterocyclic Aspartyl Protease Inhibitors | CHRM1, CHRM2, CHRM5 | RXFP1 641/4885KMT2A 1989/4885MEN1 965/4885 |
| US-20060281729-A1 | Macrocyclic heterocyclic aspartyl protease inhibitors | CHRM1, CHRM2, CHRM5 | RXFP1 641/4885KMT2A 1989/4885MEN1 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.